Income statement
CAD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 7M | 35M | 119M | 93M | 46M |
| Gross Profit | 1M | 13M | 24M | 13M | 14M |
| Operating Income | -12M | -6M | -6M | -1M | -17M |
| EBITDA | -11M | 438K | -7M | -539K | 8M |
| Net Income | -45M | -168K | -11M | -2M | 3M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.1258
-0.16% today
1Y Change
-77.80%
Window
Jun 20, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 20, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SRx Health Solutions Inc. (SRXH) is a Healthcare stock with listed on AMEX. The stock last traded around $0.13 and down 77.8% across the available one-year price window (Jun 20, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -81.3%, EPS growth of -2030.0%, a dividend yield of 0.0%. What stands out right now is revenue -81.3%, EPS -2030.0%, free cash flow -150.1% with operating margin -10.0% and ROIC 5.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SRXH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SRXH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SRXH Max Drawdown
-84.10%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SRXH and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$46.0M
-50.3% YoY
FY Net Income
$3.0M
+221.9% YoY
Free Cash Flow
-$12.2M
-489.6% YoY
Revenue Growth
-81.3%
EPS Growth
-2030.0%
Gross Margin
20.1%
Net Margin
302.1%
Income statement
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 7M | 35M | 119M | 93M | 46M |
| Gross Profit | 1M | 13M | 24M | 13M | 14M |
| Operating Income | -12M | -6M | -6M | -1M | -17M |
| EBITDA | -11M | 438K | -7M | -539K | 8M |
| Net Income | -45M | -168K | -11M | -2M | 3M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 3M | 2M | 2M | 29M |
| Total Assets | 8M | 16M | 65M | 35M | 77M |
| Total Liabilities | 8M | 7M | 71M | 34M | 20M |
| Shareholder Equity | 407K | -55M | -6M | 927K | 58M |
| Total Debt | 6M | 45M | 39M | 18M | 10M |
| Net Debt | 4M | -585K | 37M | 16M | -19M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
12M
-450.9% YoY
Capital Expenditures
353K
-44.2% YoY
Free Cash Flow
12M
-489.6% YoY
Key ratios
Gross Margin
20.1%
Operating Margin
-10.0%
Net Margin
302.1%
ROE
435.9%
Debt / Equity
5.97x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.